Lucid Diagnostics prices 18M shares at $1.00 in registered direct offering

Lucid Diagnostics (LUCD) announced the pricing of an underwritten registered direct offering of 18M common shares at a purchase price of $1.00 per share, anchored by a $15M investment from a fundamental institutional investor with support from a large existing shareholder. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $18M. The offering is expected to close on or about April 24, subject to customary closing conditions. Canaccord Genuity and BTIG are acting as joint bookrunners for the offering.